Octaplasmalg (B) (Human Plasma Protein)

Human plasma protein, the active ingredient in Octaplasmalg (B), is a plasma protein (solvent/detergent‑treated plasma) presented as a solution for injection for intravenous use. It is used to replace coagulation factors and plasma proteins in patients with bleeding disorders, massive hemorrhage, or plasma protein deficiencies.

GNH USA supplies Octaplasmalg (B) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octaplasmalg (B) provides plasma protein support for disorders of coagulation and plasma volume.

- Replacement therapy for coagulation factor deficiencies: restores missing clotting factors to achieve hemostasis. - Management of massive hemorrhage or massive transfusion protocols: supplies a broad spectrum of factors to control bleeding. - Correction of plasma protein deficiencies (e.g., hypoalbuminemia): replenishes albumin and other proteins to improve oncotic pressure. - Reversal of anticoagulation (e.g., warfarin) when rapid plasma replacement is needed: supplies functional clotting factors to counteract anticoagulant effect. - Support in liver disease or surgical settings requiring plasma protein supplementation: provides necessary proteins for coagulation and volume maintenance.

Adverse reactions may occur with any plasma‑derived product and should be monitored during and after infusion.

Common Side Effects: - Fever or chills - Mild hypotension - Headache - Transfusion‑associated circulatory overload (TACO) - Mild allergic rash or urticaria - Nausea

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Transfusion‑related acute lung injury (TRALI) - Severe hypotension or shock - Hemolytic transfusion reaction - Viral transmission (rare due to donor screening) - Disseminated intravascular coagulation (DIC) in susceptible patients

Use of Octaplasmalg (B) requires careful clinical assessment and monitoring.

- Verify compatibility: confirm blood type and perform cross‑match before infusion. - Monitor volume status: avoid fluid overload in patients with cardiac or renal impairment. - Assess infection risk: ensure donor screening and product testing have been completed. - Observe for allergic reactions: have emergency medications ready to treat anaphylaxis. - Use aseptic technique: maintain sterility during preparation and administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplasmalg (B) may interact with other therapies that affect coagulation or fluid balance.

Major Interactions (Avoid): - Concurrent plasma products: may cause volume overload. - High‑dose anticoagulants: can diminish the intended hemostatic effect. - Fibrinolytic agents: increase risk of uncontrolled bleeding.

Moderate Interactions (Monitor Closely): - Diuretics: may alter fluid balance; monitor electrolytes. - Immunosuppressants: heightened infection risk; observe for signs of infection. - Other blood components (e.g., red cells, platelets): monitor for additive volume and electrolyte shifts.